Market Overview

Cell Therapeutics Granted Market Access in Italy for PIXUVRI


Cell Therapeutics (NASDAQ: CTIC) today announced that the Company has been granted market access by the Italian Medicines Agency (AIFA) for the medicinal product PIXUVRI® (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (patients with aggressive B-cell NHL who failed 2 or 3 prior lines of therapy). Pixantrone has been classified by AIFA for use in hospitals and additional details on the pricing and reimbursement conditions for PIXUVRI in Italy will be provided coincident with the publication of the "Determina" of AIFA in the Official Gazette, which is expected to take 6 to 8 weeks.

Posted-In: News Global


Related Articles (CTIC)

View Comments and Join the Discussion!

NRG Energy Announces Commencement of 19.575M Share IPO of NRG Yield at $19.00-$21.00/Share

Astex Pharmaceuticals to Submit IND Application to FDA for ASTX727